| Cat. No. |
Product Name |
Information |
| PC-45575 |
CHZ-868
JAK2 inhibitor
|
CHZ-868 (CHZ868) is a potent type II JAK2 inhibitor, inhibits the proliferation of SET2 JAK2 V617F cells (GI50=59 nM). |
| PC-45448 |
GLPG-0634
JAK1/2 inhibitor
|
Filgotinib (GLPG 0634) is a potent JAK1/JAK2 inhibitor with IC50 of 10 nM/28 nM in biochemical assays, less potent for JAK3 and TYK2. |
| PC-42751 |
CYT387
JAK1/2 inhibitor
|
Momelotinib (CYT387) is a potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM. |
| PC-21900 |
CEP-33779
JAK2 inhibitor
|
CEP-33779 is a potent, selective, and orally bioavailable inhibitor of JAK2 with IC50 of 1.3 nM, 65-fold selective over JAK-3. |
| PC-21734 |
ATI-1777
JAK1/3 inhibitor
|
ATI-1777 is a potent, selective and ATP-competitive JAK1/3 inhibitor with IC50 of 1.5/3.6/7.1/19.0 nM for JAK1/JAK2/JAK3/TYK2, respectively. |
| PC-21596 |
JNJ-64251330
JAK inhibitor
|
Lorpucitinib (JNJ-64251330) is potent, selective and orally bioavailable pan-JAK inhibitor with IC50 of 0.37/8.6/92/7.4 nM for JAK1/JAK2/JAK3/Tyk2 respectively. |
| PC-21425 |
WHI-P131
JAK3 inhibitor
|
WHI-P131 (JANEX-1) is a potent and selective JAK3 inhibitor with Ki of 2.3 uM and IC50 of 78 uM, with no activity agianst JAK1 and JAK2. |
| PC-21376 |
MMT3-72
JAK inhibitor
|
MMT3-72 is a gastrointestinal locally-activating Janus kinase (JAK) inhibitor, readily converted to MMT3-72-M2 in the colon contents (JAK1 IC50=10.8 nM, JAK2 IC50=26.3 nM and TYK2 IC50=91.6 nM). |
| PC-21281 |
QL-1200186
TYK2-JH2 inhibitor
|
QL-1200186 is a potent, highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 0.06 nM, targets pseudokinase regulatory domain (Janus homology 2, JH2) of the TYK2 protein. |
| PC-21236 |
ABBV-712
TYK2-JH2 inhibitor
|
ABBV-712 is a potent, selective inhibitor of tyrosine kinase 2 (TYK2) with EC50 of 0.01 uM, binds and stabilizes the pseudokinase (JH2) domain of TYK2. |
| PC-21215 |
GDC-4379
JAK inhibitor
|
GDC-4379 is a potent, selective and inhaled JAK inhibitor, reduces FeNO and peripheral biomarkers of inflammation. |
| PC-20901 |
YLIU-5-162-1
JAK2 inhibitor
|
YLIU-4-105-1 is a novel type II JAK2 inhibitor, binds to JAK2 kinase domain (JH1), show potential for overcoming acquired resistance to ruxolitinib. |
